Sector News

GSK sells French research center to Oncodesign

September 29, 2016
Life sciences

GlaxoSmithKline (GSK) has sold its François Hyafil Research Centre in Villebon-sur-Yvette (Essonne), France, to Oncodesign, the buyer said today.

In return, GSK agreed to pay Oncodesign €35 million ($39 million) to support the facility over 4 years. Oncodesign said it would use the money to integrate the site and its operations into its business and ensure the continued employment of the center’s 57 employees during the period.

The agreement is expected to be completed on or about December 1.

“It will allow Oncodesign to boost its drug discovery programs and experimentation businesses and to position itself as a leading player in the business of full drug discovery services, a new market for Oncodesign,” Philippe Genne, Ph.D., the company’s CEO and founder, said in a statement.

Dr. Genne added that the acquisition of the research center will expand Oncodesign’s presence in France’s Paris-Saclay regional innovation cluster—as well as accelerate the company’s partnership launched in January with Bristol-Myers Squibb (BMS), and partnerships with Ipsen and UCB. The pharma giants are among Oncodesign’s more than 600 clients.

“In addition, it will speed up our Nanocyclix-based drug discovery internal programs through increased capabilities and productivity in both oncology and nononcology areas,” Dr. Genne added.

The research center was established in 1987, and has been based at its current site since it opened in 2010. The center was designed to support drug discovery and incubate new science within GSK by providing scientific expertise and resources that included delivery of medicinal chemistry, biology, in vivo pharmacology, and drug metabolism/pharmacokinetics capabilities with experience in many therapeutic areas.

After GSK opted to consolidate its R&D operations around two major hubs—Stevenage, U.K., and the Upper Providence site in Collegeville, PA—the pharma giant said in September 2015 it would seek a buyer for the François Hyafil Research Centre.

GSK employs more than 3500 people in France, where it has three production sites, a clinical research center, and a head office in Marly-le-Roi. Oncodesign is a drug discovery firm and oncology pharmacology service provider that employs 108 people and is based in Dijon, France.

Source: GEN

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.